Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 92881 | 66.93 |
09:34 ET | 13537 | 66.46 |
09:36 ET | 22523 | 66.14 |
09:38 ET | 42660 | 66.065 |
09:39 ET | 15748 | 66.265 |
09:41 ET | 20349 | 65.9652 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 25.7B | -4.3x | --- |
ICON PLC | 23.8B | 33.2x | +4.68% |
Biontech SE | 28.2B | -51.1x | --- |
Biogen Inc | 28.2B | 24.5x | -18.14% |
Grifols SA | 7.2B | 36.0x | --- |
Beigene Ltd | 26.5B | -44.2x | --- |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.7B |
---|---|
Revenue (TTM) | $5.1B |
Shares Outstanding | 384.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.66 |
EPS | $-15.37 |
Book Value | $36.27 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 5.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.